MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

Search

Organon & Co

Gesloten

SectorGezondheidszorg

9.93 -1

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

9.73

Max

10.06

Belangrijke statistieken

By Trading Economics

Inkomsten

-22M

87M

Verkoop

-79M

1.5B

K/W

Sectorgemiddelde

3.375

39.564

Dividendrendement

0.83

Winstmarge

5.75

Werknemers

10,000

EBITDA

-13M

325M

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

+33.33% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

0.83%

2.40%

Volgende Winsten

5 aug 2025

Volgende dividenddatum

11 sep 2025

Volgende Ex Dividend datum

15 aug 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-1.6B

2.5B

Vorige openingsprijs

10.93

Vorige sluitingsprijs

9.93

Nieuwssentiment

By Acuity

50%

50%

174 / 376 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Organon & Co Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

11 jul 2025, 22:19 UTC

Acquisities, Fusies, Overnames

FCC Approves U.S. Cellular Sale to T-Mobile

11 jul 2025, 17:28 UTC

Belangrijke Marktbewegers

SharpLink Gaming Gains on Ethereum Purchase

11 jul 2025, 16:57 UTC

Winsten

BASF Cuts Outlook on Global Economy Uncertainty

11 jul 2025, 21:45 UTC

Marktinformatie

Fitch Affirms Germany's Rating, Sees Deficit, Debt Rising -- Market Talk

11 jul 2025, 19:46 UTC

Acquisities, Fusies, Overnames

Kraft Heinz Might Split Up, Report Says. What Investors Need to Know. -- Barrons.com

11 jul 2025, 19:45 UTC

Marktinformatie

Crude Futures Post Back-to-Back Weekly Gains -- Market Talk

11 jul 2025, 19:05 UTC

Marktinformatie

U.S. Natural Gas Futures Post Third Straight Weekly Loss -- Market Talk

11 jul 2025, 18:18 UTC

Marktinformatie

Canada Officials Tight-Lipped on Next Steps in Trump Trade Talks -- Market Talk

11 jul 2025, 17:35 UTC

Marktinformatie

Canada Should Target Lower Sectoral Tariffs, Import Quotas in US Trade Talks -- Market Talk

11 jul 2025, 17:26 UTC

Marktinformatie

U.S. Oil Rig Count Down by 1 to 424 -- Market Talk

11 jul 2025, 16:53 UTC

Marktinformatie

Crude Futures Add to Early Gains -- Market Talk

11 jul 2025, 16:42 UTC

Winsten

BASF Cuts Outlook on Global Economic Uncertainty

11 jul 2025, 16:08 UTC

Marktinformatie

Rise in Canadian Staycations May Help Explain Labor Market Strength -- Market Talk

11 jul 2025, 16:05 UTC

Winsten

BASF Will Publish Half-Year Results on July 30

11 jul 2025, 16:04 UTC

Marktinformatie

Global Equities Roundup: Market Talk

11 jul 2025, 16:04 UTC

Marktinformatie

Senior Housing Shortage Gives REITs Pricing Power -- Market Talk

11 jul 2025, 16:03 UTC

Winsten

BASF: Guidance Cut Is Due to Ongoing Macroeconomic, Geopolitical Uncertainties

11 jul 2025, 16:02 UTC

Winsten

BASF Continues to Expect Free Cash Flow Between EUR400M and EUR800M in 2025

11 jul 2025, 16:01 UTC

Winsten

BASF Had Seen Ebitda Before Special Items Between EUR8B and EUR8.4B in 2025

11 jul 2025, 16:00 UTC

Winsten

BASF Now Sees Ebitda Before Special Items Between EUR7.3B and EUR7.7B in 2025

11 jul 2025, 15:59 UTC

Winsten

BASF Cuts 2025 Earnings View

11 jul 2025, 15:58 UTC

Winsten

Nvidia's CEO Has Sold a Million Shares. He Has Millions More to Sell. -- Barrons.com

11 jul 2025, 15:57 UTC

Winsten

BASF 2Q EBIT Before Special Items EUR810M

11 jul 2025, 15:54 UTC

Winsten

BASF: Analysts Had Expected 2Q Sales of EUR15.80B

11 jul 2025, 15:54 UTC

Winsten

BASF 2Q Sales Fell 2.1% on Year

11 jul 2025, 15:53 UTC

Winsten

BASF 2Q Sales EUR15.77B

11 jul 2025, 15:52 UTC

Winsten

BASF: This Was in Line With Consensus Estimates

11 jul 2025, 15:52 UTC

Winsten

BASF 2Q Ebitda Before Special Items EUR1.77B

11 jul 2025, 15:49 UTC

Winsten

BASF Reports Preliminary 2Q Figures, Adjusts 2025 Outlook

11 jul 2025, 15:41 UTC

Marktinformatie

Oil, Gas Prices Not Seen Supporting Drilling Boom -- Market Talk

Peer Vergelijking

Prijswijziging

Organon & Co Prognose

Koersdoel

By TipRanks

33.33% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 13.36 USD  33.33%

Hoogste 18 USD

Laagste 9.5 USD

Gebaseerd op 8 Wall Street-analisten die 12-maands prijsdoelen bieden voor Organon & Co - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

8 ratings

2

Buy

4

Hold

2

Sell

Technische score

By Trading Central

8.53 / 9.18Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Bearish Evidence

Lange Termijn

No Evidence

Sentiment

By Acuity

174 / 376 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Organon & Co

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.